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Abstract 
Aims: To assess the value of transient elastography for predicting significant fibrosis or 
cirrhosis in chronic hepatitis B or C (CHB or CHC) patients.  
Methods: 75 patients (CHB: 45, CHC: 32) were included. All underwent elastography and 
liver biopsy concurrently. Biopsies were evaluated using Ishak’s classification. Fibrosis 
was mild, moderate or severe/cirrhosis when scores were 0–1 (n = 30), 2–3 (n = 20), 4–6 
(n = 25), respectively.  
Results: Median liver stiffness values were higher in patients with severe fibrosis or 
cirrhosis than in those with moderate or mild fibrosis (14.8 vs. 6.4 vs. 5.3 kPa, p < 0.001). 
The diagnostic accuracy of elastography for severe fibrosis and cirrhosis was excellent 
[area under the receiver operating characteristic (AUROC) curve 0.938 vs. 0.948], but it 
was not optimal for mild fibrosis (AUROC 0.78). Values of 7.5, 9.0 and 12 kPa had a 
sensitivity and specificity for severe fibrosis/cirrhosis of 96, 84 and 60%, and 76, 90 and 
94%, respectively. The median stiffness value in cirrhotic patients (score 5–6) was 16.6 
kPa (7.7–48). No differences in accuracy of elastography between CHB or CHC patients 
were found. Cutoff was 12.5 kPa for cirrhosis; 10/75 patients (13%) were misclassified.  
Conclusion: Transient elastography has an excellent diagnostic accuracy for severe 
fibrosis and cirrhosis in CHB and CHC, but the cutoffs need further evaluation.  
Case Rep Gastroenterol 2011;5:63–72 
DOI: 10.1159/000316635 
Published online: 
January 29, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
64
Introduction 
Fibrosis is the final result of chronic liver diseases regardless of etiology. The extent 
of fibrosis is essential not only for the prognosis but also for the treatment of chronic 
liver diseases. Liver biopsy remains the gold standard for the assessment of liver fibrosis. 
However, it is an invasive procedure and not without risks. Moreover, liver histological 
lesions change with time, stressing the need for periodic assessment of liver histology 
by repeated liver biopsies, which increase the cost, give rise to questions concerning 
life quality and ethical issues, and are often refused by the patients. All these aspects 
together with the possibility of complications [1], sampling errors [2], and inter- and 
intra-pathologists variability [3] have stimulated the research for non-invasive markers 
of fibrosis.  
Transient elastography is a new, non-invasive method that measures liver tissue 
stiffness. Transient elastography by Fibroscan samples a volume of approximately 4 cm
3, 
which is more representative of liver tissue than a liver biopsy specimen. Measurements 
can usually be performed quickly and are highly reproducible, while they may be 
inaccurate or impossible in patients with obesity, ascites or narrow intercostal spaces [4]. 
Transient elastography has also been demonstrated to be a reliable tool for assessing 
fibrosis and cirrhosis mainly in patients with chronic hepatitis C (CHC) [5, 6]. Although 
there are some studies evaluating the accuracy of elastography in patients with chronic 
liver diseases of other etiologies [7, 8], more data are required in these settings, 
particularly in patients with chronic hepatitis B (CHB), who represent a large group of 
patients with chronic liver disease in many areas worldwide.  
The purpose of this study was to assess the accuracy of liver stiffness measurement by 
elastography for the diagnosis of severe fibrosis and cirrhosis as estimated by liver biopsy 
in patients with CHB or CHC. 
Materials and Methods 
Patient Population 
We included 75 consecutive patients with chronic viral hepatitis (CHB: n = 45, CHC: n = 32) who 
underwent transient elastography and liver biopsy at the same time from July 2007 until October 2008. 
Patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection, detectable antibodies 
against hepatitis delta virus (anti-HDV) or against human immunodeficiency virus (anti-HIV), other 
causes of liver injury (alcohol abuse, use of known hepatotoxic drugs, autoimmune hepatitis, metabolic 
or cholestatic liver diseases) and malignancy were excluded. No patient had decompensated liver disease 
(history or evidence of ascites, variceal bleeding, hepatic encephalopathy or jaundice). The diagnosis of 
CHB was made in cases who were HBsAg positive for at least 6 months, who had increased alanine 
aminotransferase (ALT) activity [ALT > upper limit of normal (ULN)] on at least two separate monthly 
determinations within the last 6 months and serum HBV DNA >2,000 IU/ml. The diagnosis of CHC 
was made in cases with detectable antibodies against HCV (anti-HCV) and HCV RNA in serum. 
Methods 
Data about weight and height on the liver biopsy day as well as about average alcohol consumption 
during the 5 years preceding the liver biopsy, smoking, concurrent diseases and treatment were 
recorded from all patients. Alcohol abuse was defined as a mean daily consumption of >60 g of alcohol 
for male and >40 g for female patients over the last 6 months. Full blood count including platelet count  
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(PLT), prothrombin time and liver function tests [ALT, aspartate aminotransferase (AST), alkaline 
phosphatase (ALP), gamma-glutamyl-transpeptidase (GGT)] were evaluated by commercially available 
assays in all patients on the liver biopsy day. Commercially available enzyme immunoassays were used 
for the detection of HBV markers (HBsAg, HBeAg, anti-HBe), anti-HCV and anti-HIV and 
commercially available polymerase chain reaction assays for the detection of serum HBV DNA and 
HCV RNA.  
Transient Elastography 
All transient elastographies were performed by one of two operators (M.-V.P., H.K.) and the result 
was considered reliable when the success rate (valid to total measurements) was >60% and the 
interquartile range (IQR) <30% of the final liver stiffness, as previously suggested by others [9]. 
Liver Histology 
All 75 patients had an adequate biopsy specimen with a length of ≥1.5 cm. All liver biopsies were 
evaluated by one blinded liver histopathologist (G.K.) and the histological changes of chronic hepatitis 
were classified according to the classification proposed by Ishak et al. [10]. The chronic hepatitis 
grading score (0–18), which represents the necroinflammatory activity, was the sum of piecemeal 
necrosis score (0–4), confluent necrosis score (0–6), focal lytic necrosis, apoptosis and focal 
inflammation score (0–4) and portal inflammation score (0–4). The chronic hepatitis staging score  
(0–6), which is referred to as the fibrosis score, was based on the degree and extent of fibrosis, 
architectural alterations and development of cirrhosis. Fibrosis score 0–1 was considered as absence 
of fibrosis or mild fibrosis. Advanced staging or significant fibrosis was considered as a staging/fibrosis 
score of 4–6 and cirrhosis as a staging/fibrosis score of 5–6. 
Statistical Analysis 
All data were analyzed using the statistical package SPSS 15.0. Quantitative variables with normal 
distribution were expressed as mean values ± standard deviation (SD) and those with abnormal 
distribution as median values (range). Statistical analysis was performed using t test or Mann-Whitney 
test for comparisons of quantitative variables between groups, Spearman’s coefficient for correlations of 
quantitative variables and corrected χ
2 method or two-tailed Fisher’s exact test for qualitative data, when 
appropriate. Transient elastography was evaluated using the liver stiffness both as a quantitative and 
qualitative variable after having classified patients into groups according to their liver stiffness (≤12.5 or 
>12.5 kPa) for prediction of cirrhosis. The accuracy of transient elastography for predicting no/mild 
fibrosis, significant fibrosis or cirrhosis was assessed by the area under the receiver operating 
characteristic (ROC) curve. A two-tailed p value of <0.05 was considered to be statistically significant. 
Results 
The baseline characteristics of all patients are presented in table 1. Patients with CHB 
compared to those with CHC were more frequently males and had a higher mean value 
of liver stiffness. According to the stage of fibrosis, most (29/75 or 39%) of our patients 
had no or mild fibrosis, while significant fibrosis or cirrhosis was observed in 25 (33%) 
of the 75 patients. Patients with significant fibrosis or cirrhosis compared to those with 
moderate, compared to those with no or mild fibrosis were older (mean ± SD age: 56 ± 11 
vs. 50 ± 14 vs. 43 ± 13 years, p = 0.003), had a relatively higher BMI (26 ± 5 vs. 26 ± 2 vs. 
24 ± 3 kg/m
2, p = 0.059), worse necroinflammatory activity (7 ± 3 vs. 5 ± 2 vs. 4 ± 2, p < 
0.001), and greater liver stiffness (16.8 ± 9.5 vs. 6.6 ± 2.8 vs. 5.8 ± 2.2 kPa, p = <0.001). 
Liver stiffness was found to be significantly associated with the fibrosis stage (p < 
0.001), but there was wide overlap in the values of liver stiffness among the different  
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stages of fibrosis (fig. 1). In particular, the mean (SD) liver stiffness (kPa) was 5.8 (2.2), 
6.6 (2.8), 11.3 (5.0) and 19.4 (5.0) in patients with fibrosis stage 0–1, 2–3, 4 and 5–6, 
respectively (p < 0.001). 
Liver stiffness was found to have moderate accuracy for predicting absence of fibrosis 
(stage 0–1) (c-statistic: 0.784) without significant difference between patients with CHB 
or CHC. The accuracy of prediction for moderate fibrosis did not substantially change 
(c-statistic: 0.747) when only patients with elastography with IQR <30% of liver stiffness 
were included. 
On the contrary, liver stiffness was found to have excellent accuracy for predicting 
severe fibrosis (stage 4–6) (c-statistic: 0.926) in all patients as well as in patients with CHB 
(c-statistic: 0.902) or CHC (c-statistic: 0.952) (fig. 2). The accuracy of prediction for 
severe fibrosis did not change significantly (c-statistic: 0.940) when only patients with 
elastography with IQR <30% of liver stiffness were included. 
The accuracy of liver stiffness for predicting cirrhosis (stage 5–6) was also excellent 
(c-statistic: 0.948) without significant difference between patients with CHB or CHC 
(c-statistic: 0.930 vs. 0.960) (fig. 3). Again, there was no change in the accuracy of 
prediction for cirrhosis (c-statistic: 0.960) when only patients with elastography with IQR 
<30% of liver stiffness were included. 
When a widely proposed cutoff value of 12.5 kPa for predicting cirrhosis was used, 10 
(13%) of the 75 patients were found to be misclassified (5 with cirrhosis overestimation, 
5 with cirrhosis underestimation). Misclassified patients were older, more obese, under 
antiviral therapy and had a wider range of liver stiffness measurements (IQR >30%) 
(table 2). In our population, transient elastography underestimated 29.4% of cirrhotic 
patients. On the other hand, 8.6% of the patients were classified as cirrhotic by transient 
elastography, while no cirrhosis was observed according to the biopsy specimen. 
Discussion 
Chronic viral hepatitis is an important issue of public health worldwide, which is 
associated with increased morbidity and mortality. The main therapeutic goal for patients 
with chronic viral hepatitis is the prevention of cirrhosis-associated complications and 
hepatocellular carcinoma. Assessment of the degree of hepatic fibrosis is important not 
only to determine the prognosis of chronic liver disease but also to select patients for 
treatment and to monitor the success of treatment. Despite the significant progress in 
diagnosis and therapeutic intervention over the last decade, there is still a substantial 
proportion of patients that cannot be treated effectively [11]. Additionally, because of 
the high cost and the potential side effects of the anti-HCV agents and the unknown, 
perhaps indefinite, treatment duration of oral anti-HBV agents, therapy may often be 
recommended in patients with significant histological lesions or a high risk of worsening 
liver histology. Thus, staging is important for the estimation of prognosis and decision for 
therapeutic intervention. 
Liver biopsy is currently the gold standard for the assessment of liver fibrosis. 
However, it is an invasive procedure associated with patient discomfort and occasionally 
with serious complications. In addition, the accuracy of the procedure is limited due to 
intra- and inter-observer variability and sampling errors [1–3]. Even when biopsy is  
Case Rep Gastroenterol 2011;5:63–72 
DOI: 10.1159/000316635 
Published online: 
January 29, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
67
performed and interpreted by an expert, it has an error rate in disease staging of up to 
20%. Moreover, liver histological lesions change with time, stressing the need for periodic 
assessment of liver histology by repeated liver biopsies, which, however, increase the cost, 
give rise to questions concerning life quality and ethical issues and, most importantly, are 
often refused by the patients. 
The limitations of percutaneous liver biopsy
 and particularly the difficulty in 
performing repeated procedures have increased the need for non-invasive means to assess 
liver histological lesions. Different approaches to estimate liver fibrosis non-invasively 
have been proposed, including indirect fibrosis tests based on routine liver function 
parameters, direct fibrosis tests based on extracellular matrix proteins and physical 
methods that estimate fibrosis by measuring liver stiffness. 
Transient elastography by Fibroscan is a relatively new, easy to perform, and 
promising technique that estimates the degree of hepatic fibrosis by measuring liver 
stiffness [4]. Fibroscan samples a volume of approximately 4 cm
3, which is more 
representative of the entire liver than a needle biopsy specimen. Measurements are 
quickly performed and are highly reproducible. Liver stiffness measurements range from 
2.5 to 75 kPa.  
In this study, liver stiffness values were found to be significantly associated with the 
extent of fibrosis, but there were significant overlaps in these values among patients with 
different histological stages (fig. 1). This finding is in accordance with the results of other 
studies [9], which also showed wide overlaps of liver stiffness values between adjacent 
stages of hepatic fibrosis, particularly for mild stages of fibrosis. 
The area under ROC curve for the prediction of no or mild fibrosis was 0.784 and there 
was no liver stiffness value offering both sensitivity and specificity over 70%. The accuracy 
of liver stiffness values for the prediction of severe fibrosis and cirrhosis was excellent 
with areas under ROC curves being >0.90 when CHB and CHC patients were analyzed 
together or separately. These findings are also in agreement with previous reports further 
supporting the excellent overall predictability of Fibroscan of the presence of advanced 
fibrosis or cirrhosis in patients with chronic viral hepatitis [9, 12]. Despite the excellent 
results from the ROC curves analyses, however, it was impossible to identify very strong 
cutoff stiffness values in our patients. In particular, no stiffness value offered both 
sensitivity and specificity over 80% for the prediction of severe fibrosis or cirrhosis. 
The stiffness cutoff values for cirrhosis have been reported to range from 10.3 kPa in 
patients with CHB [13] to 17.3 kPa in patients with cholestatic diseases [7], but the 
optimal cutoff value remains to be determined. Using the stiffness cutoff value of 12.5 kPa 
proposed by Castera et al. [14] for the prediction of cirrhosis in patients with CHC, we 
examined the cases with discordance between transient elastography and liver biopsy 
findings. We found that 13% of our 75 patients were misclassified (7% in the study of 
Castera et al. [14]). In particular, cirrhosis was overestimated by Fibroscan in 5 and 
underestimated in another 5 cases. The 10 patients misclassified compared to patients 
correctly classified by elastography were older, under antiviral treatment and had more 
frequently an unreliable test (IQR >30% of the median value [9]). The latter characteristic 
may be, at least partly, responsible for the relatively rarer misclassification rate in the 
study of Castera et al., in which only patients with IQR <30% of the median stiffness 
values were included [14]. It should be noted, however, that many patients with 
elastographies considered to be unreliable (IQR >30% of liver stiffness) were classified  
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correctly according to their liver stiffness measurements, and therefore the exclusion of 
these cases did not affect the overall accuracy of prediction of elastography in our study. 
In conclusion, our data further support that liver stiffness measurements by transient 
elastography are strongly associated with the extent of fibrosis [9, 12]. Fibroscan’s 
diagnostic accuracy for the presence of advanced fibrosis or cirrhosis in patients with 
chronic viral hepatitis was found to be excellent (AUROC >0.90). We should keep in 
mind that, as recently suggested by Mehta et al. [15], even in the best scenario where liver 
biopsy accuracy is highest, the calculated AUROC would be 0.90. However, transient 
elastography cannot replace liver biopsy yet, particularly in the initial evaluation of 
patients with chronic viral hepatitis, mainly because it may misclassify approximately 10% 
of cases for the presence of cirrhosis [14]. Moreover, liver biopsy offers additional 
information on all types of histological lesions and not only on liver fibrosis. The optimal 
cutoff of liver stiffness values for the prediction of cirrhosis and whether this may be 
specifically defined for each type of chronic liver disease remains to be determined [16]. 
In our study, there was no difference in the prognostic accuracy of elastography for the 
extent of fibrosis between patients with CHB and CHC. Since transient elastography is 
easy to perform and has excellent patient acceptance, it seems to be very useful for 
monitoring changes of fibrosis in the individual patient. It should be noted, however, that 
the potential effect of treatment on the accuracy of elastography has not been adequately 
studied to date and, therefore, more data in patients under therapy should be obtained 
before the wide establishment of such a use of elastography in routine clinical practice. 
 
 
 
Table 1. Baseline characteristics of 75 patients with CHB or CHC 
 CHΒ 
(n = 43) 
CΗC 
(n = 32) 
Total 
(n = 75) 
p 
Sex, males (%)  0.33 (77)  0.16 (50)  0.49 (65)  0.017 
Age, years  0.48 ± 14  .051 ± 13   .049 ± 14  0.419 
Height, m  01.7 ± 0.1  01.7 ± 0.1  01.7 ± 0.1  0.836 
Weight, kg  72.8 ± 11.7  72.6 ± 13.6  72.7 ± 12.4  0.930 
BMI, kg/m
2  25.2 ± 2.7  25.4 ± 4.3   25.3 ± 3.5  0.851 
Other diseases, n (%)  00.8 (19)  00.8 (25)  0.16 (21)  0.357 
Alcohol, n (%)  .006 (14)  .004 (12)  .010 (13)  0.259 
Smoking, n (%)  0.16 (37)  0.16 (50)  0.32 (43)  0.135 
Under therapy, n (%)  .019 (44)  .014 (44)  .033 (44)  0.882 
Necroinflammation  00.5 ± 2  00.5 ± 2  00.5 ± 2  0.443 
Fibrosis  .003 ± 2  .003 ± 2  .003 ± 2  0.369 
Liver stiffness, kPa  07.7 ± 5.0  12.3 ± 9.7  09.7 ± 7.7  0.009 
BMI = Body mass index. 
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Table 2. Characteristics of correctly and falsely classified patients in relation to the presence of cirrhosis 
and the stiffness cutoff of 12.5 kPa at transient elastography 
  Correct classification  
(n = 65) 
Wrong classification 
(n = 10) 
p 
Sex, males (%)  0.42 (65)  00.7 (70)  0.739 
Age, years  .047 ± 13  .063 ± 11  0.001 
ΒΜΙ, kg/m
2  25.3 ± 3.5  25.1 ± 3.6  0.844 
Type of CH, n (%) 
CΗΒ 
CΗC  
 
0.37 (57) 
.028 (43) 
 
00.6 (60) 
.004 (40) 
 
 
0.855 
Under therapy, n (%)  0.24 (37)  00.9 (90)  0.001 
Other diseases, n (%)  .012 (18)  .004 (40)  0.140 
Drugs, n (%)  0.20 (31)  00.6 (60)  0.075 
Alcohol, n (%)  .008 (12)  .002 (20)  0.713 
Smoking, n (%)  0.30 (46)  00.2 (20)  0.027 
IQR/stiffness (>30%)   .056 (86)  00.5 (50)  0.006 
BMI = Body mass index; IQR = interquartile range. 
 
 
 
 
 
Fig. 1. Liver stiffness values by elastography for each stage of fibrosis. Box and whisker plots express 
median values and interquartile and overall ranges. Liver stiffness values are significantly higher in 
more severe stages of fibrosis (p < 0.001), but there are significant overlaps among the different fibrosis 
stages. 
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Fig. 2. ROC curve for the prediction of severe fibrosis (stage 4–6) by liver elastography. Liver stiffness 
values have excellent overall accuracy for predicting severe fibrosis (c-statistic: 0.926) in all patients with 
CHB or CHC (A) as well as in patients with CHB only (c-statistic: 0.902) (B) or patients with CHC only 
(c-statistic: 0.952) (C). 
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Fig. 3. ROC curve for the prediction of cirrhosis (stage 5–6) by liver elastography. The accuracy of liver 
stiffness for predicting cirrhosis is excellent in all patients with CHB or CHC (c-statistic: 0.948) (A) as 
well as in patients with CHB only (c-statistic: 0.930) (B) or patients with CHC only (c-statistic: 0.960) 
(C). 
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